Advocacy intelligence hub — real-time data for patient organizations
Yorvipath: FDA approved
treatment of hypoparathyroidism in adults
Natpara: FDA approved
An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance3
Yorvipath
(palopegteriparatide)Orphan drugAscendis Pharma Bone Diseases A/S
12.1 Mechanism of Action At physiological conditions, palopegteriparatide releases PTH(1-34) to maintain a continuous systemic exposure. Endogenous PT...
Natpara
(parathyroid hormone)Orphan drugTakeda Pharmaceuticals U.S.A., Inc.
Parathyroid Hormone [EPC]
12.1 Mechanism of Action NATPARA is a parathyroid hormone. Parathyroid hormone raises serum calcium by increasing renal tubular calcium reabsorption, ...